A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab

OBJECTIVE: A nomogram model based on clinical variables was conducted to predict the survival in patients with non‐small cell lung cancer (NSCLC) receiving second‐line atezolizumab. METHODS: Four hundred and twenty‐four patients with NSCLC receiving atezolizumab from OAK study were regarded as the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Xiaoling, Shi, Jianxiang, Wang, Xiaohui, Zhao, Chenglong, Yu, Haining, Wang, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446569/
https://www.ncbi.nlm.nih.gov/pubmed/34331414
http://dx.doi.org/10.1002/cam4.4160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446569/
https://www.ncbi.nlm.nih.gov/pubmed/34331414
http://dx.doi.org/10.1002/cam4.4160

Ejemplares similares